Tilray Stock Slides as Market Awaits Clarity on Cannabis Reform
Tilray’s stock has been on a rough ride lately, and the situation seems to be getting more tense by the day. Over the past several weeks, the share price has slipped dramatically—from a high of $23.15 in early October to just $7.20 now. And what’s making investors even more nervous is that the chart is now on the verge of forming what traders call a “death cross,” a well-known bearish signal that often points to further downside.
So, here’s what’s going on when we look at the technical picture. Tilray’s stock had previously surged from a split-adjusted low of $3.58 in June to that October peak, but almost all of those gains have now evaporated. The price has dropped below every major moving average on the daily chart, and the 50-day EMA is now about to cross below the 200-day EMA. That’s the classic death cross pattern, and it usually reflects a shift toward a longer-term downtrend.
Also Read:Adding to that, the stock hasn’t just broken down—it has plunged through an important support level at $10.35, which had held since September 11. Momentum indicators like the RSI and Stochastic Oscillator have both fallen deep into oversold territory, while the ADX continues to climb, signaling that the downward trend is actually strengthening, not weakening. If the current pressure continues, the next key level many traders are watching is the psychological floor at around $5. A strong move back above $10.35, however, would shake off the bearish picture and open the door for a recovery toward $15.
But Tilray’s challenges aren’t just technical—they’re also tied to broader uncertainty in the cannabis sector. The whole industry has been under heavy pressure. The popular MSOS ETF has dropped about 40% since August, and big names like Curaleaf, Trulieve, Green Thumb, and Cresco Labs have all seen steep declines. One major reason is political: Donald Trump has stayed silent on the potential reclassification of cannabis, after previously suggesting a decision was close. Without clarity, investors have taken a cautious—and often pessimistic—stance.
On the business side, Tilray is dealing with its own hurdles. The company has invested heavily in beverages, but that segment reported slightly weaker revenue—$55.7 million compared to $56 million a year earlier. That trend matches the broader slowdown in the beer industry, which has weighed on companies like Boston Beer and Molson Coors as well. The bright spot comes from Tilray’s cannabis segment, where revenue rose 5% to $64.5 million, along with growth in wellness and distribution. The company also strengthened its balance sheet by trimming $7.7 million in debt and maintaining a healthy cash position of over $268 million.
Ultimately, the direction of Tilray’s stock may depend heavily on one thing: whether or not Trump finally speaks up about cannabis reclassification. A supportive move could spark a rebound. Continued silence may keep the pressure on.
Read More:
0 Comments